Trials / Completed
CompletedNCT06207877
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment(CagriSema) on Energy Intake, Appetite and Gastric Emptying in People With Overweight or Obesity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This research study tests if CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight. Participant will either get CagriSema (active medicine) or placebo (a dummy medicine), which has no effect on the body. The treatment participants get is decided by chance. The study will last for about 32 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cagrilintide | Cagrilintide will be administered subcutaneously. |
| DRUG | Semaglutide | Semaglutide will be administered subcutaneously. |
| DRUG | Placebo | Placebo will be administered subcutaneously. |
Timeline
- Start date
- 2024-02-23
- Primary completion
- 2024-10-16
- Completion
- 2024-11-22
- First posted
- 2024-01-17
- Last updated
- 2026-01-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT06207877. Inclusion in this directory is not an endorsement.